Literature DB >> 6132358

The effect of ethanol on GABAergic transmission.

W A Hunt.   

Abstract

One of the many actions of ethanol involves the GABAergic system. The interaction of ethanol with GABAergic neurons is a complex one involving both presynaptic and postsynaptic sites. Through a presumed fluidization of membranes after a single dose of ethanol, the available in vitro evidence suggests that ethanol disrupts the normal functioning of the GABA-benzodiazepine-chloride ionophore complex in a complicated manner involving a sequential activation of different active sites leading to the facilitation of GABA transmission. This finding has been supported in vivo using electrophysiological techniques. Presynaptic GABAergic neurons may experience a reduced activity, especially at low doses of ethanol. After chronic ethanol treatment, GABAergic transmission may be reduced, especially during an ethanol withdrawal syndrome. Also, other changes in the GABA-benzodiazepine-chloride ionophore complex suggest GABA transmission is suppressed postsynaptically. Drugs which enhance the actions of GABA may be suitable inhibitors of the ethanol withdrawal syndrome. In particular a new class of drugs, the triazolopyridazines, may be promising compounds for treatment of withdrawal with a more specific mode of action and fewer side effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6132358     DOI: 10.1016/0149-7634(83)90009-x

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  15 in total

Review 1.  The benzodiazepine receptor.

Authors:  S A Bergman
Journal:  Anesth Prog       Date:  1986 Sep-Oct

2.  Convulsant properties of GABA antagonists and anticonvulsant properties of ethanol in selectively bred long- and short-sleep mice.

Authors:  T J Phillips; D Kim; B C Dudek
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Genotype-dependent effects of GABAergic agents on sedative properties of ethanol.

Authors:  B C Dudek; T J Phillips
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Site-specific enhancement of gamma-aminobutyric acid-mediated inhibition of neural activity by ethanol in the rat medial septal area.

Authors:  B S Givens; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1990-08       Impact factor: 4.030

5.  Ethanol self-administration in freely feeding and drinking rats: effects of Ro15-4513 alone, and in combination with Ro15-1788 (flumazenil).

Authors:  H L June; R W Hughes; H L Spurlock; M J Lewis
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

6.  Autoradiographic study on [3H]flunitrazepam binding in rat cortex and hippocampus after chronic ethanol treatment.

Authors:  M Negro; A Fernández; P Calvo
Journal:  Neurochem Res       Date:  1992-04       Impact factor: 3.996

7.  Ro 15-4513 selectively attenuates ethanol, but not sucrose, reinforced responding in a concurrent access procedure; comparison to other drugs.

Authors:  N M Petry
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

8.  Sex differences in the neurotoxic effects of adenosine A1 receptor antagonism during ethanol withdrawal: reversal with an A1 receptor agonist or an NMDA receptor antagonist.

Authors:  Tracy R Butler; Katherine J Smith; Rachel L Self; Brittany B Braden; Mark A Prendergast
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

Review 9.  Sex differences in neuroadaptation to alcohol and withdrawal neurotoxicity.

Authors:  Lynda Sharrett-Field; Tracy R Butler; Anna R Reynolds; Jennifer N Berry; Mark A Prendergast
Journal:  Pflugers Arch       Date:  2013-04-05       Impact factor: 3.657

10.  Involvement of diazepam-insensitive benzodiazepine receptors in the suppression of DOI-induced head-twitch responses in diabetic mice.

Authors:  Shigeo Miyata; Shoko Hirano; Junzo Kamei
Journal:  Psychopharmacology (Berl)       Date:  2006-03-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.